Indication

Secondary progressive multiple sclerosis

Secondary progressive multiple sclerosis is an advanced phenotypic phase of multiple sclerosis affecting the central nervous system, occurring in individuals who initially presented with a relapsing-remitting disease course. Read more about Secondary progressive multiple sclerosis

103 drugs 53 manufacturers

Advertisement

Drugs that treat it

Common Secondary progressive multiple sclerosis therapies.

Showing 91–99 of 103 drugs

DIMETHYL FUMARATE

MULTIPLE SCLEROSIS AGENTS, GENERAL·RELAPSING FORM OF MULTIPLE SCLEROSIS·+1
Allen's Cylinder

MITOXANTRONE HCL

ANTHRACYCLINE ANTIBIOTICS·ACUTE MYELOID LEUKEMIA·+3
FRESENIUS KABI

DIMETHYL FUMARATE

MULTIPLE SCLEROSIS AGENTS, GENERAL·RELAPSING FORM OF MULTIPLE SCLEROSIS·+1
MACLEODS PHARMA

MITOXANTRONE HCL

ANTHRACYCLINE ANTIBIOTICS·ACUTE MYELOID LEUKEMIA·+3
MEITHEAL PHARMA

GLATIRAMER ACETATE

GLATIRAMER (MULTIPLE SCLEROSIS)·RELAPSING FORM OF MULTIPLE SCLEROSIS·+1
SUN PHARMACEUTI

GLATIRAMER ACETATE

GLATIRAMER (MULTIPLE SCLEROSIS)·RELAPSING FORM OF MULTIPLE SCLEROSIS·+1
ZYDUS PHARMACEU

GILENYA (fingolimod HCl)

MULTIPLE SCLEROSIS AGENTS, GENERAL·RELAPSING FORM OF MULTIPLE SCLEROSIS·+1
Novartis Pharmaceuticals

GLATIRAMER ACETATE

GLATIRAMER (MULTIPLE SCLEROSIS)·RELAPSING FORM OF MULTIPLE SCLEROSIS·+1
Upsher-Smith Laboratories
Filter & compare in the drug finder →Opens the drug finder with Secondary progressive multiple sclerosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Secondary progressive multiple sclerosis.

Secondary progressive multiple sclerosis is an advanced phenotypic phase of multiple sclerosis affecting the central nervous system, occurring in individuals who initially presented with a relapsing-remitting disease course.

It is clinically defined by an insidious, irreversible accumulation of neurological impairment and physical or cognitive disability that progresses independently of acute attacks.

Pathophysiologically, the disease shifts from predominantly focal, relapsing inflammatory demyelination toward diffuse neurodegeneration, compartmentalized central nervous system inflammation, microglial activation, and axonal loss.

Clinical presentation is further characterized as either active or non-active based on the presence of superimposed relapses or new magnetic resonance imaging activity, as well as with or without progression.

Personalize your experience

Follow Secondary progressive multiple sclerosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it